Synthesis of Functionalized Azomethine Ylides via the Rh(II)-Catalyzed Cyclization of .alpha.-Diazo Carbonyls onto Imino .pi.-Bonds
摘要:
alpha-Diazo carbonyl compounds containing an imino group in the gamma-position have been found to undergo a rhodium(II) acetate induced cyclization reaction to generate cyclic azomethine ylides. The reactive dipole undergoes a subsequent 1,3-dipolar cycloaddition with added dipolarophiles. The imino/oxime nitrogen lone pair of electrons must be properly oriented so as to interact with the rhodium carbenoid. Thus, acyclic oxime ethers which exist in the proper E-configuration readily undergo the tandem cyclization-cycloaddition reaction. In sharp contrast, the isomeric Z-oximino diazo carbonyl system does not cyclize to an azomethine ylide but rather intramolecularly inserts into the oximino C-H bond. Addition of a catalytic amount of rhodium(II) acetate to (E)-2-(diazoacetyl)benzaldehyde O-methyloxime in the presence of DMAD or N-phenylmaleimide affords a dipolar cycloadduct in high yield. When p-quinone was used as the dipolarophile, the initially formed cycloadduct was treated with acetic anhydride to give a compound containing the basic core dibenzo[a,d]cyclohepten-5,10-imine skeleton found in MK-801. Cyclic imines such as isoxazolines were particularly effective substrates for azomethine ylide formation. The rhodium(II) catalyzed reaction of 3-(4-diazo-3-oxobutyl)-5-phenyl-Delta(2)-isoxazoline with DMAD produced a 4:1 mixture of diastereomeric cycloadducts in good yield. Cyclization of the rhodium carbenoid did not occur with the aromatic isoxazole system and this is presumably due to the low basicity of the nitrogen lone pair of electrons.
SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
申请人:Merck Sharp & Dohme Corp.
公开号:US20180305320A1
公开(公告)日:2018-10-25
The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
本发明涉及式I化合物:以及药用可接受的盐。此类化合物可用于治疗RORgammaT介导的疾病或状况。
SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
申请人:Merck Sharp & Dohme Corp.
公开号:US20180016239A1
公开(公告)日:2018-01-18
The present invention relates to compounds according to Formula (I-1) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
Ethyl Lithiodiazoacetate: Extremely Unstable Intermediate Handled Efficiently in Flow
作者:Simon T. R. Müller、Tobias Hokamp、Svenja Ehrmann、Paul Hellier、Thomas Wirth
DOI:10.1002/chem.201602133
日期:2016.8.16
The generated ethyl lithiodiazoacetate is highly reactive and decomposes rapidly, even at lowtemperatures. Herein, we report a continuous flow protocol that overcomes the problems associated with the instantaneous decomposition of ethyl lithiodiazoacetate. The addition of ethyl lithiodiazoacetate to ketones provides direct access to tertiary diazoalcohols in good yields.
[EN] DIHYDROPYRANOPYRIMIDINES FOR THE TREATMENT OF VIRAL INFECTIONS<br/>[FR] DIHYDROPYRANOPYRIMIDINES POUR LE TRAITEMENT D'INFECTIONS VIRALES
申请人:JANSSEN SCIENCES IRELAND UC
公开号:WO2018002319A1
公开(公告)日:2018-01-04
This invention relates to dihydropyranopynmidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
本发明涉及二氢吡喃吡啶啉衍生物,其制备方法,药物组合物以及它们在治疗病毒感染中的应用。
An enantioselective approach to the Securinega alkaloids: the total synthesis of (+)-norsecurinine and (+)-allonorsecurinine
作者:Matthew R. Medeiros、John L. Wood
DOI:10.1016/j.tet.2010.03.015
日期:2010.6
Total syntheses of (+)-norsecurinine and (+)-allonorsecurinine are described that utilize a rhodium carbenoid-initiated O–H insertion/Claisen rearrangement/1,2-allyl migration domino process for the stereoselective introduction of the tertiary alcohol moiety. Overall the employed strategy is flexible and will allow access to other members of the Securinega family of alkaloids.